Primary resistance to integrase strand-transfer inhibitors in Europe: Table 1.

HIV Prevention in Clinical Care Settings

(2014) Jeanne M. Marrazzo et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

(2014) A. Castagna et al.   JOURNAL OF INFECTIOUS DISEASES

The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults

(2012) Mark R. Underwood et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy

(2011) Benjamin Young et al.   ANTIVIRAL THERAPY

Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient

(2011) Sarita D Boyd et al.   ANTIVIRAL THERAPY

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

(2011) Joseph J Eron et al.   LANCET INFECTIOUS DISEASES

Natural Polymorphisms of Human Immunodeficiency Virus Type 1 Integrase and Inherent Susceptibilities to a Panel of Integrase Inhibitors

(2009) A. Low et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences

(2009) L. C. J. Alcantara et al.   NUCLEIC ACIDS RESEARCH

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

(2008) I. Malet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of Raltegravir and Elvitegravir on HIV-1 Integrase Catalytic Reactions and on a Series of Drug-Resistant Integrase Mutants†

(2008) Jessica Marinello et al.   BIOCHEMISTRY

Implications of HIV-1 M Group Polymorphisms on Integrase Inhibitor Efficacy and Resistance: Genetic and Structuralin SilicoAnalyses†

(2008) Eriketi Z. Loizidou et al.   BIOCHEMISTRY

New treatment options for HIV salvage patients: An overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists

(2008) Amelia Hughes et al.   JOURNAL OF INFECTION

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors

(2008) O. Goethals et al.   JOURNAL OF VIROLOGY

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

(2008) David A. Cooper et al.   NEW ENGLAND JOURNAL OF MEDICINE

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

(2008) Roy T. Steigbigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors

(2008) Soo-Yon Rhee et al.   Retrovirology

Integrase Inhibitors: A New Treatment Option for Patients with Human Immunodeficiency Virus Infection

(2007) Todd Correll et al.   PHARMACOTHERAPY